Clinical trial
A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and…
NCT00087711 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00087711 |
|---|---|
| Title | A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer |
| Official title | A Randomized Phase 3 Trial of ALIMTA and Cisplatin Versus GEMZAR and Cisplatin in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Non Small Cell Lung Carcinoma |
| Intervention type | Drug |
| Interventions | pemetrexed, gemcitabine, cisplatin |
| Enrollment | 1,713 |
| Start date | Jul 1, 2004 |
| Primary completion | Jan 1, 2007 |
| Completion | Mar 1, 2008 |
| First posted | Jul 16, 2004 |
| Last update posted | Sep 12, 2019 |
| Countries | Argentina, Australia, Austria, Belgium, Brazil, Canada, Denmark, Finland, France, Germany, Greece, Hungary and 15 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: